Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18118634 | 0.81 | DHODH (0.80) | DHODHTSHRNPSR1 | |
| SCHEMBL252035 | 0.76 | DHODH (1.00) | DHODH | |
| SCHEMBL1124079 | 0.75 | DHODH (1.00) | DHODHKMT2ATSHRMEN1 | |
| SCHEMBL1124423 | 0.74 | DHODH (1.00) | DHODHKMT2AALDH1A1 | |
| SCHEMBL6430181 | 0.74 | DHODH (0.61) | DHODHKMT2ANPSR1MEN1 | |
| SCHEMBL1124110 | 0.73 | DHODH (0.66) | DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL1124081 | 0.73 | DHODH (0.73) | DHODHKMT2AMEN1 | |
| SCHEMBL18624759 | 0.72 | DHODH (0.85) | DHODHTSHRNPSR1 | |
| SCHEMBL18624760 | 0.72 | DHODH (0.85) | DHODHTSHRNPSR1 | |
| SCHEMBL1549482 | 0.72 | DHODH (0.55) | DHODHKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-1578741-B1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2283898-A1 | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-7365094-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-04-29 | — | — | US | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1581478-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578741-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056797-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | DHODH, SQOR, NDUFA5 | DHODH 1/4885KMT2A 3407/4885TSHR 4749/4885 |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885KMT2A 1965/4885TSHR 4829/4885 |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | PPARG, PPARD, PPARA | DHODH 3023/4885KMT2A 4427/4885TSHR 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.